Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

19 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Chlorpromazine Articles

UK government report slams overuse of antipsychotic drugs in dementia patients

13 November 2009

Lancet study gives further warning about the use of antipsychotics in the treatment of Alzheimer's

19 January 2009

UK AD patients face sedative death risk

9 April 2007

BMJ launches medical milestones poll

15 January 2007

India acts on prices of 87 drug formulations

9 June 2003

UK NICE OKs newer antipsychotics as a first-line option for schizophrenia

10 June 2002

UK fast track sought for clinical trial of mepacrine in treatment of CJD

20 September 2001

Tests to start on drug treatment for CJD?

14 August 2001

Zeneca's Seroquel Debuts In UK For Schizophrenia

24 September 1997

Zeneca's Seroquel Nears Market Approval

16 July 1997

Lilly Launches Zyprexa In Its First Markets

21 October 1996

Zeneca's Phase III Data Support Seroquel Efficacy

16 October 1995

PHASE II RESULTS WITH ZENECA'S SEROQUEL

4 July 1994

FURTHER CLUES TO CLOZARIL ACTION

26 April 1993

Showing 1-14 of 14 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
  • Additional indications in Japan for Roche's Avastin and Astellas' Prograf
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
  • Additional indications in Japan for Roche's Avastin and Astellas' Prograf
  • US Supreme Court says patent settlement can "sometimes" be illegal

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS